S L Marshall1, D Edidin2, V C Arena3, D J Becker4, C H Bunker1, C Gishoma5, F Gishoma5, R E LaPorte1, V Kaberuka5, G Ogle6, L Sibomana1, T J Orchard1. 1. University of Pittsburgh Graduate School of Public Health, Department of Epidemiology, Pittsburgh, PA, USA. 2. Northwestern University, Feinberg School of Medicine, Pediatrics, Chicago. 3. University of Pittsburgh Graduate School of Public Health, Department of Biostatistics, Pittsburgh, PA, USA. 4. University of Pittsburgh School of Medicine, Department of Pediatrics, Pittsburgh, PA, USA. 5. Association Rwandaise des Diabetiques, Kigali, Rwanda. 6. International Diabetes Federation Life for a Child Program and Australian Diabetes Council, Sydney, Australia.
Abstract
AIMS: To determine prevalence and incidence estimates for clinically recognized cases of Type 1 diabetes from the Life For a Child Program (LFAC) with onset < 26 years in six representative districts, and the capital, of Rwanda. METHODS: Cases were identified from the LFAC registry and visits to district hospitals. Denominators were calculated from district-level population surveys. Period prevalence data were collected from 1 August 2011 to 31 July 2012 and annual incidence rates were calculated, retrospectively, for 2004-2011. Ninety-five per cent confidence intervals (95% CI) were calculated using a Poisson distribution. RESULTS: The prevalence of known Type 1 diabetes in seven districts in Rwanda for ages < 26 years was 16.4 [95% CI 14.6-18.4]/100 000 and for < 15 years was 4.8 [3.5-6.4]/100 000. Prevalence was higher in females (18.5 [15.8-21.4]/100 000) than males (14.1 [11.8-16.7]/100 000; P = 0.01) and rates increased with age. The annual incidence rate for those < 26 years was stable between 2007 and 2011 with a mean incidence over that time of 2.7 [2.0-3.7]/100 000 ( < 15 years = 1.2 [0.5-2.0]/100 000). Incidence rates were higher in females than males and peaked in males at ages 17 and 22 years and in females at age 18 years. CONCLUSIONS: Our report of known Type 1 diabetes cases shows lower incidence and prevalence rates in Rwanda than previously reported in the USA and most African countries. Incidence of recognized cases has increased over time, but has recently stabilized. However, the likelihood of missed cases due to death before diagnosis and misdiagnosis is high and therefore more definitive studies are needed.
AIMS: To determine prevalence and incidence estimates for clinically recognized cases of Type 1 diabetes from the Life For a Child Program (LFAC) with onset < 26 years in six representative districts, and the capital, of Rwanda. METHODS: Cases were identified from the LFAC registry and visits to district hospitals. Denominators were calculated from district-level population surveys. Period prevalence data were collected from 1 August 2011 to 31 July 2012 and annual incidence rates were calculated, retrospectively, for 2004-2011. Ninety-five per cent confidence intervals (95% CI) were calculated using a Poisson distribution. RESULTS: The prevalence of known Type 1 diabetes in seven districts in Rwanda for ages < 26 years was 16.4 [95% CI 14.6-18.4]/100 000 and for < 15 years was 4.8 [3.5-6.4]/100 000. Prevalence was higher in females (18.5 [15.8-21.4]/100 000) than males (14.1 [11.8-16.7]/100 000; P = 0.01) and rates increased with age. The annual incidence rate for those < 26 years was stable between 2007 and 2011 with a mean incidence over that time of 2.7 [2.0-3.7]/100 000 ( < 15 years = 1.2 [0.5-2.0]/100 000). Incidence rates were higher in females than males and peaked in males at ages 17 and 22 years and in females at age 18 years. CONCLUSIONS: Our report of known Type 1 diabetes cases shows lower incidence and prevalence rates in Rwanda than previously reported in the USA and most African countries. Incidence of recognized cases has increased over time, but has recently stabilized. However, the likelihood of missed cases due to death before diagnosis and misdiagnosis is high and therefore more definitive studies are needed.
Authors: Sarah Blackstock; Miles D Witham; Alisha N Wade; Amelia Crampin; David Beran; Graham D Ogle; Justine I Davies Journal: BMJ Open Date: 2019-10-18 Impact factor: 2.692
Authors: Jessica L Harding; Pandora L Wander; Xinge Zhang; Xia Li; Suvi Karuranga; Hongzhi Chen; Hong Sun; Yuting Xie; Richard A Oram; Dianna J Magliano; Zhiguang Zhou; Alicia J Jenkins; Ronald C W Ma Journal: Diabetes Care Date: 2022-04-01 Impact factor: 17.152
Authors: Aida Abdraimova; Stéphane Besançon; Jill Portocarrero; Kaushik Ramaiya; Asel Dunganova; Margaret Ewen; Hans Hogerzeil; Maria Lazo-Porras; Richard Laing; Molly Lepeska; Happy Nchimbi; Assa Sidibé; Andrew Swai; Janeth Tenorio-Mucha; John S Yudkin; Jessica H Zafra-Tanaka; Aida Zurdinova; David Beran Journal: Diabet Med Date: 2022-06-06 Impact factor: 4.213